Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Qualigen Therapeutics, Inc. (RTTR)
|
Add to portfolio |
|
|
|
| Price: |
$1.12
| | Metrics |
| OS: |
5.05
|
M
| |
|
|
| Market cap: |
$5.66
|
M
| |
|
|
|
Net cash:
|
$1.34
|
M
| |
$0.27
|
per share
|
|
EV:
|
$4.32
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($17.8)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Mar-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| Revenues | 5.0 | 5.7 | 4.3 | 5.6 | 6.1 | 12.3 | 0.0 | 0.3 |
| Revenue growth | -11.9% | 31.3% | -29.7% | | -50.0% | | -100.0% | 11.9% |
| Cost of goods sold | 4.3 | 4.3 | 3.7 | 1.5 | 6.3 | 12.5 | 0.0 | 0.3 |
| Gross profit | 0.7 | 1.3 | 0.6 | 4.1 | -0.1 | -0.2 | 0.0 | 0.0 |
| Gross margin | 13.7% | 23.4% | 14.6% | 73.2% | -2.4% | -1.7% | | 0.0% |
| Selling, general and administrative | | | -3.7 | | | | | |
| Sales and marketing | 1.0 | 0.5 | | 0.4 | | | | |
| Research and development | 6.8 | 11.7 | | 0.7 | | | 2.9 | 13.3 |
| General and administrative | 10.8 | 11.7 | | 1.5 | 4.6 | 5.4 | 4.8 | 4.9 |
| EBIT | -17.9 | -22.7 | 0.0 | -1.5 | -10.8 | -17.9 | -7.9 | -18.4 |
| EBIT margin | -360.0% | -400.9% | 0.0% | -27.0% | -177.0% | -145.9% | | -6769.1% |
| Pre-tax income | -21.3 | -17.9 | -20.4 | -1.8 | -10.1 | -16.9 | -7.9 | -18.4 |
| Income taxes | -0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 1.2% | | | | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -18.6 | -17.9 | -20.4 | -1.8 | -10.1 | -16.9 | -11.0 | -18.4 |
| Net margin | -374.0% | -316.6% | -474.2% | -32.2% | -165.4% | -137.6% | | -6746.3% |
| |
| Diluted EPS | ($4.85) | ($6.10) | ($1.17) | ($0.32) | ($1.06) | ($3.18) | ($4.95) | ($2.04) |
| Shares outstanding (diluted) | 3.8 | 2.9 | 17.4 | 5.6 | 9.6 | 5.3 | 2.2 | 9.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|